Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis

Sitryx Therapeutics announced completion of enrollment in its Phase 1b clinical trial of SYX-5219, a first-in-class oral PKM2 modulator for moderate to severe atopic dermatitis, ahead of schedule. The trial enrolled 50 patients across US and European sites and is expected to readout in Q4 2026. The milestone follows positive Phase 1a data showing safety and immunomodulation of type 2 inflammation.

06/22/2026, 7:00 AM • GlobeNewswire

GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs

GSK and Spero Therapeutics announced FDA approval of Utebzi (tebipenem pivoxil hydrobromide), the first oral carbapenem antibiotic for treating complicated urinary tract infections including pyelonephritis. The drug demonstrated non-inferiority to intravenous imipenem-cilastatin in Phase 3 trials and is expected to launch in the U.S. by end of 2026, offering an alternative to hospital-based IV treatments for the 3+ million Americans annually affected by cUTIs.

06/17/2026, 1:29 PM • Benzinga

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK announced a $10.6 billion all-cash acquisition of Nuvalent at $124 per share, representing a 40% premium. The deal reflects Big Pharma's aggressive capital deployment to address an impending patent cliff, as GSK faces revenue loss from dolutegravir's expiring exclusivity. Nuvalent brings two late-stage kinase inhibitors targeting non-small cell lung cancer with FDA Breakthrough Therapy designations, triggering a short squeeze and signaling potential industry consolidation in oncology.

06/11/2026, 1:18 PM • Investing

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK agreed to acquire Nuvalent for $10.6 billion in cash, marking its largest acquisition in over a decade. The deal provides GSK with three lung cancer assets including lead drug candidates zidesamtinib and neladalkib for non-small cell lung cancer treatment. The acquisition is expected to contribute to revenue growth and be accretive to sales and core operating profit beginning in 2027.

06/09/2026, 6:52 AM • Benzinga

Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?

Eli Lilly announced three infectious disease acquisitions in a single day—Curevo (shingles vaccine), LimmaTech Biologics (bacterial pathogen vaccines), and Vaccine Company (viral infection prevention)—totaling over $3.8 billion. These deals signal management's strategy to diversify beyond its blockbuster obesity drugs (Zepbound and Mounjaro) and build new growth engines focused on disease prevention, particularly addressing antimicrobial resistance and infections linked to serious conditions like multiple sclerosis and cancer.

06/08/2026, 5:23 PM • The Motley Fool

Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035

The global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key players are investing in R&D for improved formulations and expanding into emerging markets.

05/25/2026, 5:31 AM • GlobeNewswire

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.

05/19/2026, 1:00 PM • GlobeNewswire

Sitryx to Participate in Upcoming Investor Conferences

Sitryx Therapeutics, a clinical-stage biopharmaceutical company, announced participation in three major investor conferences (Jefferies Global Healthcare, J.P. Morgan European Healthcare Forum, and Evercore Emerging Private Biotech) in June 2026. The company is developing novel oral therapies for autoimmune and inflammatory diseases, with lead candidate SYX-5219 (PKM2 modulator) showing safety and efficacy in Phase 1a trials, and a GLS1 inhibitor nominated for clinical development in asthma.

05/18/2026, 7:00 AM • GlobeNewswire

First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026

Sitryx Therapeutics announced positive Phase 1a trial results for SYX-5219, a first-in-class oral pyruvate kinase M2 (PKM2) modulator for atopic dermatitis. The drug demonstrated safety, tolerability, target engagement, and evidence of systemic immunomodulation with reduced CCL17/TARC biomarker levels. A Phase 1b trial in adults with moderate to severe atopic dermatitis is underway with data expected by year-end 2026.

05/13/2026, 7:00 AM • GlobeNewswire

GSK Targets China's Hepatitis B Market Through New Deal

GSK entered an exclusive strategic collaboration with Sino Biopharmaceutical to accelerate bepirovirsen, an investigational hepatitis B treatment, in mainland China. The drug is under priority regulatory review in China and showed positive Phase 3 trial data. GSK will retain marketing authorization and regulatory responsibility while CTTQ handles distribution and promotional activities. Additionally, GSK announced the final tranche of its £2 billion share repurchase program.

05/11/2026, 12:03 PM • Benzinga

Antibiotic Resistance Market to Grow at 5.4% CAGR Reaching USD 12.72 Billion by 2031, Driven by Rising Drug-Resistant Infections and Antimicrobial Innovation: Mordor Intelligence

The antibiotic resistance market is projected to grow from USD 9.78 billion in 2026 to USD 12.72 billion by 2031 at a 5.4% CAGR, driven by rising multidrug-resistant infections and innovations in rapid diagnostics and novel antimicrobials. North America leads the market while Asia-Pacific emerges as a high-growth region.

04/28/2026, 3:52 AM • GlobeNewswire

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

A Delaware Chancery Court dismissed Tesaro's (GSK subsidiary) anticipatory breach of contract claim against AnaptysBio, rejecting requests for royalty reductions on Jemperli. The ruling affirms Anaptys has not repudiated the collaboration agreement and validates the company's efforts to protect its contractual rights. A trial is scheduled for July 14-17, 2026, where Anaptys will pursue claims that Tesaro/GSK materially breached the agreement and seek potential reversion of Jemperli.

04/24/2026, 3:40 PM • GlobeNewswire

Omics-Based Clinical Trials Research Report 2026: $47.78 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

The omics-based clinical trials market is experiencing robust growth, expanding from $31.71 billion in 2025 to $34.49 billion in 2026 with an 8.8% CAGR, and projected to reach $47.78 billion by 2030. Growth is driven by increasing demand for personalized medicine, genomics advancements, AI-enabled patient recruitment, and biomarker-driven trial designs. North America leads the market while Asia-Pacific shows rapid expansion potential.

04/24/2026, 4:59 AM • GlobeNewswire

Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight

Over 65 pharmaceutical companies are advancing 75+ pipeline COPD drugs, with the treatment landscape evolving beyond traditional bronchodilators toward targeted biologics and anti-inflammatory therapies. Recent clinical trial successes include AstraZeneca's tozorakimab meeting primary endpoints in Phase III trials, and multiple companies progressing novel candidates through various development stages.

04/23/2026, 1:00 PM • GlobeNewswire